Orexinergic projections to the cat midbrain mediate alternation of emotional behavioural states from locomotion to cataplexy

Kaoru Takakusaki[1], Kazumi Takahashi[2], Kazuya Saitoh[1], Hirofumi Harada[1], Toshikatsu Okumura[3], Yukihiko Kayama[2] and Yoshimasa Koyama[2,4]

[1]*Department of Physiology, Asahikawa Medical College, Midorigaoka-higashi 2-1, Asahikawa 078-8510, Japan*
[2]*Department of Physiology, Fukushima Medical University School of Medicine, 1 Hikari-ga-oka, Fukushima 960-1295, Japan*
[3]*Department of General Medicine, Asahikawa Medical College, Midorigaoka-higashi 2-1, Asahikawa 078-8510, Japan*
[4]*Department of Science and Technology, Fukushima University, 1 Kanayagawa, Fukushima 960-1296, Japan*

Orexinergic neurones in the periforncial lateral hypothalamus project to structures of the midbrain, including the substantia nigra and the mesopontine tegmentum. These areas contain the mesencephalic locomotor region (MLR), and the pedunculopontine and laterodorsal tegmental nuclei (PPN/LDT), which regulate atonia during rapid eye movement (REM) sleep. Deficiencies of the orexinergic system result in narcolepsy, suggesting that these projections are concerned with switching between locomotor movements and muscular atonia. The present study characterizes the role of these orexinergic projections to the midbrain. In decerebrate cats, injecting orexin-A (60 μM to 1.0 mM, 0.20–0.25 μl) into the MLR reduced the intensity of the electrical stimulation required to induce locomotion on a treadmill (4 cats) or even elicit locomotor movements without electrical stimulation (2 cats). On the other hand, when orexin was injected into either the PPN (8 cats) or the substantia nigra pars reticulata (SNr, 4 cats), an increased stimulus intensity at the PPN was required to induce muscle atonia. The effects of orexin on the PPN and the SNr were reversed by subsequently injecting bicuculline (5 mM, 0.20–0.25 μl), a GABA$_A$ receptor antagonist, into the PPN. These findings indicate that excitatory orexinergic drive could maintain a higher level of locomotor activity by increasing the excitability of neurones in the MLR, while enhancing GABAergic effects on presumably cholinergic PPN neurones, to suppress muscle atonia. We conclude that orexinergic projections from the hypothalamus to the midbrain play an important role in regulating motor behaviour and controlling postural muscle tone and locomotor movements when awake and during sleep. Furthermore, as the excitability is attenuated in the absence of orexin, signals to the midbrain may induce locomotor behaviour when the orexinergic system functions normally but elicit atonia or narcolepsy when the orexinergic function is disturbed.

Orexinergic neurones are located in the periforncial lateral hypothalamus and project to most central nervous system areas. In addition, the orexinergic projection to the brainstem monoaminergic and cholinergic neurones mediates sleep–wakefulness regulation (Peyron *et al.* 1998; Chemelli *et al.* 1999; Lin *et al.* 1999; Nambu *et al.* 1999; Saper *et al.* 2001; Taheri *et al.* 2002). It has been reported that FOS immunohistochemical studies and neural recording studies indicate that the orexinergic neurones increase their activity during waking (Estabrooke *et al.* 2001; Alam *et al.* 2002; Koyama *et al.* 2003; Lee

et al. 2005; Mileykovskiy *et al.* 2005). When waking, orexin release increased markedly during periods of increased motor activity compared to its release during quiet, alert waking (Kiyashchenko *et al.* 2002). These findings indicate that the orexinergic system contributes to regulation of the state of vigilance and somatomotor control (Sakurai, 2002; Nishino, 2003; Siegel, 2004). It has also been considered that deficiencies in the orexinergic system result in narcolepsy (Chemelli *et al.* 1999; Lin *et al.* 1999). However the pathophysiological mechanisms by which the orexinergic system suppresses narcolepsy remain unclear.

One of the major orexinergic projections is present in the structures of the midbrain, including the substantia nigra and the mesopontine tegmentum (Peyron *et al.* 1998; Nambu *et al.* 1999). The latter contains the mesencephalic locomotor region (MLR) (Grillner *et al.* 1997; Takakusaki *et al.* 2003*a*), and the pedunculopontine and the laterodorsal tegmental nuclei (PPN/LDT) which regulate rapid eye movement (REM) sleep (McCarley *et al.* 1995; Datta & Siwek, 1997; Koyama & Sakai, 2000). Under normal conditions emotional stimuli induce alert responses which produce an increase in muscle tone and/or locomotor behaviour (Garcia-Rill *et al.* 2004; Skinner *et al.* 2004). However, humans and animals with narcolepsy may experience cataplexy, a sudden loss of muscle tone induced by emotional stimuli (Nishino & Mignot, 1997; Nishino, 2003). It is possible therefore that orexinergic projections to these areas may be involved in both locomotion and a loss of muscle tone.

Other investigations have reported that the activation of neurones in the MLR of acute decerebrate cats induced locomotion, and activation of neurones in the ventrolateral PPN-induced muscular atonia that was associated with REM (Takakusaki *et al.* 2003*a*, 2004*c*). The PPN-induced REM and atonia were associated with activation of cholinergic neurones. Moreover, an activation of neurones in the substantia nigra pars reticulata (SNr) prevented PPN-induced REM with atonia via GABAergic projections to the PPN (Takakusaki *et al.* 2004*c*). Because the orexinergic system is abnormal in the context of narcolepsy, we hypothesized that orexinergic projections to these midbrain structures may regulate the switching of emotional motor behaviour. Emotional signals elicit locomotor behaviour in the presence of orexins and induce cataplexy in the absence of orexins. Consequently, the goal of the present study was to characterize the role of orexinergic projections to the midbrain in the control of locomotion and postural muscle tone. For this purpose we employed acute decerebrate cats in which the cerebral hemispheres, including the hypothalamus, were removed. We then examined how MLR-induced locomotion, and PPN-induced REM and atonia, were altered after injections of orexin-A into each of the MLR, the PPN, and the SNr. The preliminary results have been published as abstracts (Takakusaki *et al.* 2004*d*).

Methods

All of the experimental procedures were approved by the Animal Studies Committee of Asahikawa Medical College and were in accordance with the *Guide for the Care and Use of Laboratory Animals* (NIH Guide, revised 1996). Every effort was made to minimize animal suffering and to reduce the number of animals required for these experiments.

Animal preparation

The experiments were performed with 24 cats, with a weight from 2.1 to 3.4 kg, from the animal facility at Asahikawa Medical College. Each cat was surgically decerebrated at the precollicular–postmammillary level while under halothane (Halothane, Otsuka, Osaka, Japan; 0.5–3.0%) and nitrous oxide gas (0.5–1.0 l min^{-1}) anaesthesia with oxygen (3.0–5.0 l min^{-1}). The anaesthesia was then discontinued. The trachea was intubated, and a catheter was placed in the femoral artery to monitor blood pressure. Another catheter was placed in the cephalic vein to administer adrenaline (Bosmin, Daiichi Co., Osaka, Japan). The head was fixed in a stereotaxic apparatus, and a rigid spinal frame secured the cat by clamping the dorsal processes of the first three thoracic vertebrae. The limbs rested on a static surface, or on the surface of a treadmill, and a rubber hammock supported the body. The animal's rectal temperature was maintained at 36–37°C by using radiant heat lamps. The mean blood pressure of each cat was maintained greater than 100 mmHg by an intravenous infusion of adrenaline (0.1–0.3 mg kg^{-1}, infusion rate of 0.01 mg min^{-1}), and the end tidal CO_2 was maintained between 4% and 6%.

Brainstem stimulation and EMG recording

Each stimulating electrode consisted of a glass micropipette filled with Wood's metal. The tip of the micropipette was replaced with a carbon fibre (diameter, 7 μm; resistance, 0.2–0.5 MΩ; Takakusaki *et al.* 2003*a*, 2004*c*). The experimental design is schematically illustrated in Fig. 2. A stimulating electrode was inserted into the mesopontine tegmentum (A 1.0–P 3.0, LR 2.0–5.0, H +1.0–5.0). To evoke locomotion, repetitive stimuli with a constant pulse (10–50 μA, and 0.2 ms duration at 50 Hz) were delivered for 5–30 s while the treadmill belt was advanced at a speed of 0.3 m s^{-1}. The same electrode was used for mesopontine stimulation (10–50 μA, and 0.2 ms duration at 50 Hz, lasting for 5–10 s) to evoke REM with atonia while the animal's limbs rested on a stationary surface (Takakusaki *et al.* 2003*a*, 2004*c*). The stimulation was applied by moving the stimulating electrode with an interval of 0.5–1.0 mm in the dorsoventral, mediolateral and rostrocaudal directions so that an optimal site for evoking locomotion, or REM with atonia could be identified in each animal. The optimal stimulus sites for evoking locomotion, so-called midbrain locomotor region (MLR), were mainly located in the cuneiform nucleus (CNF). The sites for evoking muscle tone suppression were located in the ventral and ventrolateral parts of the PPN (Fig. 1).

Short train pulses of stimuli (3 trains, 5 ms intervals and 40 μA) were also delivered to each of the CNF, the locus coeruleus (LC), the medial pontine reticular

formation (PRF), and the PPN, so that the excitatory and inhibitory effects from each site on muscle tone could be examined (Fig. 8). The changes in the electromyographic activity of the left soleus muscles which were evoked from each site were rectified, integrated and averaged, for 20 sweeps.

A micropipette which was filled with orexin A (60 μM to 1.0 mM) was inserted into the mesopontine tegmentum (A 1.0–P 3.0, LR 2.0–5.0, H +1.0–5.0) so that orexin could be injected into the CNF and PPN. In previous investigations we have shown that either electrical or chemical stimulation of the lateral part of the SNr inhibited the PPN-induced REM and atonia (Takakusaki *et al.* 2004*c*). Consequently, an identical type of micropipette was also inserted into the rostral midbrain (A 2.0–A 5.0, LR 3.0–7.0, H +2.0–5.0) so that orexin could be injected into the SNr. By using an oil-driven

microinjection system, 0.25 μl of orexin A was injected into these midbrain areas at a rate of approximately 0.01 μl s^{-1}. A Wilcoxon signed rank test was performed with the use of StatView statistical software (Abacus Concepts, Berkeley, CA, USA) to determine any significant difference in the stimulus intensity before and after the orexin injections (Figs 3 and 5).

A pair of stainless steel wires (2 mm apart) were inserted into the left soleus (Sol) muscles to record the electromyogram activity (EMG). All of the EMGs were processed with a low pass filter of 5 Hz and a high pass filter of 100 Hz with a time constant of 0.03 s. The electrooculograms (EOG) were recorded with a bipolar electrode placed into the lateral part of the anterior wall of the bilateral frontal sinus. The EOG activity was recorded with a low pass filter of 0.5 Hz and a high pass filter of 200 Hz with a time constant of 0.03 s.


Figure 1. Locomotion, and REM and atonia induced by midbrain stimulation
Aa, the stimulus sites for evoking locomotion (○), and REM and atonia (●), are indicated on a parasagittal plane (L 4.0). *b*, locomotion on the moving treadmill elicited by stimulation (40 μA) of the CNF. *c*, REM and atonia induced by stimulation (30 μA) of the PPN. In *b* and *c* the upper recording is an EOG, the middle and lower recordings are EMGs from the left (L) and right (R) soleus (Sol) muscles. The stimulus period is indicated by lines under each recording. *B*, optimal stimulus sites for evoking locomotion (○) and REM and atonia (●) on parasagittal (*a*) and coronal planes (*b*) of the brainstem. Locomotor evoking sites were mainly located in the CNF, and inhibitory sites were located in the ventrolateral part of the PPN. A location of the PPN where cholinergic neurones were distributed is indicated by the grey area. *Ca*, a microphotographic presentation of cholinergic neurones, which were labelled by ChAT immunohistochemistry, in the mesopontine tegmentum. The area corresponds to the area enclosed by a square in *Bb*. *b*, higher magnification of the area enclosed by a square in *a*. Abbreviations: IC, inferior colliculus; CNF, cuneiform nucleus; L, lateral; LDT, laterodorsal tegmental nucleus; MLR; midbrain locomotor region; NRPo, nucleus reticularis pontis oralis; P, posterior; PPN, pedunculopontine tegmental nucleus; REM, rapid eye movements; SC, superior colliculus; SCP, superior cerebellar peduncle; SNr, substantia nigra pars reticulata.

Histological control

At the end of an experiment, the stimulus sites were marked by passing a direct current of 30 μA through an electrode for 30 s. The injection sites were also marked with 10% fast green, using the same amount as the substances that had been previously injected. Each cat was then killed with an overdose of sodium pentobarbital (60 mg kg^{-1}, I.P.) anaesthesia. The brainstem was removed and fixed in 10% formalin. Frozen coronal or parasagittal sections (50 μm) were cut and stained with neutral red. The location of the microlesions and diffusion areas of the fast green were identified with the assistance of the stereotaxic atlases of Berman (1968) and Snider & Niemer (1961).

Choline acetyltransferase (ChAT) immunohisto-chemistry was performed to identify the boundaries of the PPN so that we could elucidate whether the effective stimulus sites for evoking REM and atonia were located within the PPN. Six animals were deeply anaesthetized with Nembutal and transcardially perfused with 0.9% saline followed by a solution of 3.0% paraformaldehyde and 0.01% glutaraldehyde in 0.1 M phosphate buffer (pH 7.4). The brain of each cat was removed and saturated with a cold solution of 30% sucrose, and 50 μm frozen sections were prepared. Following this, ChAT immunohistochemistry was performed by using the peroxidase–antiperoxidase method combined with diaminobenzidine (Mitani *et al.* 1988; Lai *et al.* 1993; Takakusaki *et al.* 2003*a*, 2004*a*). Monoclonal anti-ChAT antibody (Boehringer Mannheim, Germany) was used for these preparations.

Results

Locomotor region and muscle tone inhibitory region in the midbrain

Before examination of the effects of the orexin injections into the mesopontine tegmentum, we confirmed the stimulus effects of the locomotor region and muscle tone inhibitory region in the mesopontine tegmentum, as described in a previous report (Takakusaki *et al.* 2003*a*). The findings shown in Fig. 1*A* illustrate that repetitive electrical stimulation applied to the CNF induced locomotion on the moving treadmill (Fig. 1*Ab*). On the other hand, stimulation of the ventral part of the PPN resulted in suppression of postural muscle tone and generation of REM (REM and atonia). The distribution of the optimal stimulus sites for evoking locomotion, and the muscle tone inhibitory region, are shown on parasagittal (Fig. 1*Ba*) and coronal (Fig. 1*Bb*) planes of the brainstem. It was confirmed that the locomotor region was mainly located in the CNF and partly included the dorsal region of the PPN. The muscle tone inhibitory region was located in the ventrolateral region of the PPN. The distribution of the cholinergic neurones, which were labelled by ChAT immunohistochemistry on a coronal section of the brainstem, is shown in Fig. 1*C*. ChAT- positive, cholinergic neurones were located in the LDT and the PPN (Fig. 1*Ca*). The PPN was defined by loosely arranged cholinergic neurones that surrounded the superior cerebellar peduncle (SCP; Fig. 1*Ca*). The cholinergic neurones were preferentially distributed in an area corresponding to the inhibitory region, rather than the locomotor region.

A framework for this study

Figure 2 shows a framework for this study. The MLR and muscle tone inhibitory region in the PPN are in close proximity to each other in the lateral part of the midbrain (Takakusaki *et al.* 2003*a*, 2004*a*,*c*). Activation of the MLR induces locomotor movements via activation of central pattern generators in the spinal cord through the medullary reticulospinal tract (Rossignol, 1996). Activation of the MLR may also activate muscle tone excitatory systems, including the coerulospinal and


Figure 2. A framework for the present study
See text for explanation.

raphespinal tracts (Mori, 1987; White & Fung, 1989). In contrast, activation of the PPN neurones induces REM and atonia. The PPN-induced muscular atonia is mediated through the pontomedullary reticulospinal tract (inhibitory system; Habaguchi *et al.* 2002; Takakusaki *et al.* 2003*a*, 2004*a,c*). It is suggested that an interconnection between the mesopontine cholinergic nuclei and the caudoventral PRF could operate as a common generator of REM and ponto-geniculo-occipital waves (Sakai & Jouvet, 1980; Datta & Hobson, 1994; Vanni-Mercier & Debilly, 1998). The PPN-induced REM can be thus attributed to an activation of the REM generator in the PPN and the caudal PRF (Takakusaki *et al.* 2004*c*). Electrophysiological (Saitoh *et al.* 2003) and neuroanatomical (Grofova & Zhou, 1998) studies have suggested that GABAergic neurones in the SNr monosynaptically inhibit the activity of cholinergic PPN neurones. We have demonstrated that the PPN effects were

under the control of GABAergic inhibitory projections from the SNr (Takakusaki *et al.* 2003*a*, 2004*c*).

Effects of injections of orexin A into the midbrain areas

Orexinergic neurones project to the mesopontine tegmentum, including the MLR, the PPN and the SNr. Consequently, orexin A (0.1–0.25 μl, 60 μM to 1 mM) was injected into each of these areas to characterize how MLR/PPN-induced locomotion and REM and atonia were altered by these orexinergic projections. First, we examined the effects of an orexin injection into the MLR (Fig. 3). Electrical stimulation (30 μA) which was applied to the lateral part of the CNF (indicated by a filled arrow in Fig. 3*A*) elicited locomotion on the moving treadmill. However stimuli with a strength of 20 μA did


Figure 3. Orexin controls locomotor movements

A, a stimulus site (a filled arrow) and an orexin injection site (an open arrow) on coronal sections of the mid-brain. *B*, upper and lower traces are electromyographic activity obtained from the left (L) and right (R) soleus (Sol) muscles. *a*, before an orexin injection stimulation of the CNF with an intensity of 20 μA did not evoke locomotor movements on the moving treadmill. *b*, locomotor movements were evoked 10 min after an orexin injection (200 μM, 0.25 μl) into the CNF. In *a* and *b* the treadmill speed was 0.3 m s^{-1} throughout the period of each trial. *c*, locomotor movements were observed without electrical stimulation and 30 min after the orexin injection. The treadmill speed was 0.3 m s^{-1}. The open bar under the EMG recording indicates the period of moving treadmill. *Ca*, locomotion elicited by stimulating the CNF with an intensity of 40 μA. *b*, twenty minutes after an orexin injection (60 μM, 0.25 μl) into the CNF, stimuli with an intensity of 20 μA elicited locomotion. *c*, CNF stimulation with an intensity of 30 μA elicited locomotion 60 min after the injection. In each trial the treadmill speed was 0.3 m s^{-1}. *D*, changes in threshold stimulus intensity for evoking locomotion. The threshold current of any trial was reduced after the orexin injections. For the trials indicated by the symbols, the concentrations of the injected orexin were: ○, 60 μM; □, 100 μM; ■, 200 μM; and ●, 500 μM. The threshold currents for evoking locomotion before (mean ± standard deviation = 31.2 ± 7.5 μA, median = 30 μA) and after (mean ± standard deviation = 12.5 ± 7.5 μA, median = 15 μA) the orexin injections were significantly different (*P* = 0.005). Abbreviation: PRF, pontine reticular formation.

not evoke locomotion (Fig. 3*Ba*). Next, orexin A with a concentration of 200 μM and a volume of 0.25 μl was injected into the region adjacent to the locomotor region (indicated by an open arrow in Fig. 3*A*). Ten minutes after this injection stimulation with a strength of 20 μA evoked locomotion. Thirty minutes after the injection locomotion was elicited on the treadmill belt (indicated by an open line under the EMG records) without electrical stimulation (Fig. 3*Bc*). In another cat (Fig. 3*C*) stimulation of the CNF with a strength of 40 μA elicited locomotion (Fig. 3*Ca*). Twenty minutes after an injection of orexin (60 μM, 0.25 μl) into the CNF a stimulus strength of 20 μA was enough to evoke locomotion (Fig. 3*Cb*). Even 60 min after the injection locomotion was still evoked by stimuli with a strength of 30 μA (Fig. 3*Cc*). The complete effects of the orexin upon locomotion were examined in 10 trials in six cats. In each trial the threshold current to elicit locomotion was reduced (Fig. 3*D*). Moreover, injections of orexin with higher concentrations (200 and 500 μl) spontaneously induced locomotion without electrical stimulation in two animals.

Next, the effect of orexin injections into the PPN was examined. In the cat illustrated in Fig. 4*A*, stimulation of the caudal part of the PPN (indicated by a filled arrow in Fig. 4*Aa*) induced REM and atonia (Fig. 4*Ab*). Orexin A was then injected into the PPN adjacent to the stimulus site (indicated by an open arrow in Fig. 4*Aa*). It was generally observed that an orexin injection into the PPN alone did not change the level of muscle tone. However, 30 min after the injection of orexin, REM and atonia were abolished when the PPN was stimulated with the same intensity (Fig. 4*Ac*). In eight cats, orexin injections into the PPN either abolished the PPN effects, even when stimuli with an intensity of 50 μA were delivered (3 trials in 3 cats), or attenuated the PPN effects (8 trials in 5 cats). Figure 4*B* illustrates that the threshold stimulus strength which was required to elicit the PPN effect was increased in each trial after the orexin injections. These findings suggest


Figure 4. Orexin controls PPN-induced REM and atonia
A, the effects of an orexin injection into the PPN on PPN-stimulus effects. *a*, a stimulus site (a filled arrow) and an orexin injection site (an open arrow) in the PPN area are shown on coronal sections of the mesopontine tegmentum. *b*, from upper to lower: an EOG and EMGs of the left and right soleus muscles. Stimulation (30 μA and 50 Hz) of the PPN induced REM and muscular atonia. The REM was induced only during the period of the stimulation, which is denoted by a line below the recording. *c*, an orexin injection (200 μM, 0.25 μl) into the PPN abolished the PPN-induced REM and atonia. *B*, the threshold stimulus strength which was required to elicit the PPN effect was increased in each trial after the orexin injections. For the trials indicated by the symbols, the concentrations of the injected orexin were: ○, 60 μM; □, 100 μM; ■, 200 μM; ●, 500 μM; and ▲, 1000 μM. The stimulus strength which was required to elicit muscular atonia was compared in 8 trials in 5 cats. The threshold currents for eliciting muscular atonia before (23.8 $\pm$ 5.2 μA, 25 μA) and after (42.5 $\pm$ 4.6 μA, 45 μA) the orexin injections were significantly different ($P = 0.003$). *C*, the effects of bicuculline injection into the PPN. *a*, muscular atonia induced by PPN stimulation (25 μA and 50 Hz). *b*, 20 min after the injection of orexin (1000 μM, 0.25 μl) into the PPN, the PPN-induced muscular atonia was abolished. *c*, a bicuculline injection (1 mM, 0.25 μl) into the PPN, 20 min after the orexin injection, reversed the PPN effect. A line below each recording indicates the period of PPN stimulation.

that the orexinergic projection to the PPN suppresses the excitability of PPN neurones that are involved in the generation of REM and atonia.

Because an activation of cholinergic neurones in the PPN induces REM and atonia (Takakusaki *et al.* 2003*a*, 2004*a*,*c*), it is possible that orexin inhibits cholinergic neurones in the PPN. However, orexin excites cholinergic neurones located in the LDT (Burlet *et al.* 2002; Takahashi *et al.* 2002). Because non-cholinergic neurones, in particular GABAergic neurones, are located in the PPN (Ottersen & Storm-Mathisen, 1984; Kosaka *et al.* 1988; Ford *et al.* 1995), we attempted to examine whether an orexin injection indirectly inhibited cholinergic PPN neurones via local GABAergic interneurones in the PPN. The results that are shown in Fig. 4*C* illustrate that an injection of bicuculline into the PPN after an orexin injection restored the PPN stimulus effects that were disturbed by the orexin. Essentially the same results were obtained from two other animals. This suggests that orexin inhibits cholinergic PPN neurones via GABAergic effects.

Further attempts were made to test whether orexinergic projections to the SNr could affect the PPN-induced REM and atonia via the GABAergic nigrotegmental projection (see Fig. 2). The results are shown in Fig. 5. After confirming REM and atonia (Fig. 5*Ab*), which was induced by the PPN stimulation (indicated by a filled arrow in Fig. 5*Aa*), orexin A was injected into the dorso-lateral part of the SNr (indicated by an open arrow in Fig. 5*Aa*). Although the orexin injection into the SNr did not alter the level of the muscle tone it did result in complete inhibition of the PPN-induced REM and atonia (Fig. 5*Ac*). In eight trials of four animals, orexin injections increased the stimulus strength that was required to produce the PPN-induced REM and atonia (Fig. 5*B*). In another cat PPN-induced muscular atonia (Fig. 5*Ca*) was blocked by an orexin injection into the SNr (Fig. 5*Cb*). To further determine whether the effect of a nigral orexin injection was mediated through GABAergic projections to the PPN, bicuculline was injected into the PPN. It was observed that the PPN-induced muscular atonia was


Figure 5. Orexinergic input to the SNr controls PPN-induced REM and atonia
A, the effects of an orexin injection into the SNr on the PPN effects. *a*, the sites of the stimulus (a filled arrow) in the PPN, and the injection of orexin (an open arrow) in the SNr, on coronal sections of the midbrain. *b*, from upper to lower: an EOG and EMGs obtained from the left and right soleus muscles. REM and atonia induced by PPN stimulation (30 μA and 50 Hz). *b*, an orexin injection (200 μM, 0.25 μl) into the SNr abolished the PPN effects. *B*, the strength of the threshold stimulus which was required to elicit the PPN effect was increased in each trial (8 trials in 4 cats) after the orexin injections. The trials and concentrations of orexin injected were: □, 100 μM; ■, 200 μM; ●, 500 μM; and ▲, 1000 μM. The stimulus strength which was required to elicit muscular atonia was compared in 7 trials with 4 cats. The threshold currents for eliciting muscular atonia before (23.8 $\pm$ 4.9 μA, 25 μA) and after (39.3 $\pm$ 4.5 μA, 40 μA) the orexin injections were significantly different ($P = 0.011$). *C*, the effects of bicuculline injection into the PPN. *a*, muscular atonia induced by PPN stimulation (30 μA and 50 Hz). *b*, 30 min after an orexin injection (1000 μM, 0.25 μl) into the SNr, the PPN-induced muscular atonia was not observed. *c*, a subsequent bicuculline injection (1 mM, 0.25 μl) into the PPN, 30 min after the orexin injection, reversed the PPN effect. A line below each recording indicates the period of PPN stimulation.

re-established 5 min after the injection of bicuculline (Fig. 5*Cc*). These results indicate that PPN-induced REM and atonia is inhibited by the GABAergic nigrotegmental projection.

Orexin injection sites and time course of the orexin effects

Fast green was used to identify the injection sites and to measure the spread of the infusions, which for each injection was limited to an area of approximately 1.0–1.5 mm in diameter. Figure 6 illustrates the locations of the injection sites on coronal (Fig. 6*A–C*) and parasagittal planes (Fig. 6*D*) of the brainstem. Ten injection sites which either facilitated MLR-induced locomotion or spontaneously elicited locomotion were located in an area corresponding to the CNF and adjacent region, including the dorsal part of the PPN (Fig. 6*A* and *D*). Injection sites which inhibited the PPN effects were located in a region corresponding to the PPN ($n = 11$, Fig. 6*B* and *D*) and the lateral part of the SNr ($n = 8$, Fig. 6*C*

and *D*). Two injections, which are indicated by an asterisk in Fig. 6*D*, not only facilitated MLR-induced locomotion but also inhibited PPN-induced REM and atonia.

The relationship between the time course of the effects and the concentration of the orexin injected into the CNF (6 trials), the PPN (4 trials) and the SNr (4 trials) is shown in Fig. 7. The orexin effects were determined by the threshold current for evoking either the MLR-induced locomotion (Fig. 7*A*) or the PPN-induced muscular atonia (Fig. 7*B* and *C*). The orexin effects usually started to appear 10 min after an injection, reached a maximum level 30–40 min later, and lasted for more than 100 min. Moreover the effects were considered to be dose dependent. For example, in the case of orexin injections into the PPN (Fig. 7*B*) stronger effects were induced with higher concentrations (200 and 500 μM) than with lower concentrations (60 and 100 μM). Figure 7*D* shows the time course of the effects of a bicuculline injection into the PPN. The bicuculline was injected 20–30 min after the orexin into either the PPN (filled and open triangles) or the SNr (filled and grey squares). The bicuculline produced


Figure 6. Effective injection sites for orexin A

A, most of the sites of injections which facilitated MLR-induced locomotion ($n = 10$) were located in the CNF and an adjacent area, including the dorsal part of the PPN. *B*, the sites of injections which inhibited PPN-induced REM and atonia ($n = 11$) were located in the ventrolateral part of the PPN. In *A* and *B*, the effective sites are plotted on coronal planes of the mesopontine tegmentum at the levels of AP0, P1, and P2. *C*, the sites of injections which inhibited PPN-induced REM and atonia ($n = 8$) are illustrated on coronal planes of the rostral midbrain at the levels of A3 and A4. The sites covered an area corresponding to the dorsolateral part of the SNr. *D*, the injection sites are illustrated on a parasagittal plane of the brainstem at the level of LR4–5. There was a clear functional topography in the orexinergic control of locomotion and postural muscle tone. Two injections, which are indicated by an asterisk, not only facilitated MLR-induced locomotion but inhibited PPN-induced REM and atonia. Abbreviations: A, anterior; AP, anterior-posterior; CP; cerebral peduncle; LR, left and right.

a decrease in the threshold current required for evoking the PPN effects which, in any trials, appeared within 5 min.

Modulation of descending excitatory and inhibitory effects upon muscle tone

Finally, we elucidated how orexin injections into the PPN modulate the descending excitatory and inhibitory effects on muscle tone (Fig. 8). We first stimulated each of the CNF, the LC, the PRF, the dorsal PPN and the ventral

PPN to examine the stimulus effects on soleus muscle activity (Fig. 8*B*). We then compared these effects with the results obtained by the same stimulus procedures, but after an injection of orexin (Figs 8*C* and *D*). Short trains of stimuli which were applied to the CNF and the LC (indicated by open circles in Fig. 8*A*) induced a mixture of excitatory and inhibitory effects on the muscle tone (1st and 2nd recordings in Fig. 8*B*). In contrast, stimuli applied to the medial PRF and the dorsal and ventral PPN areas (indicated by filled circles in Fig. 8*A*) induced prominent inhibitory effects (3rd and 5th recordings in


Figure 7. The time course of the orexin effects
A–C, the time course of the effects of the orexin injections into the CNF (*A*), PPN (*B*) and SNr (*C*) are shown with respect to the different concentrations of orexin. *A*, an orexin injection reduced the threshold current for evoking MLR-induced locomotion. In 5 of 6 trials the orexin effect was observed within 10 min of the injection. Locomotor movement induced by the moving treadmill without stimulation was observed when higher concentrations (200 μM and 500 μM) of orexin were injected into the CNF. *B*, orexin injections into the PPN increased the threshold current required for evoking PPN atonia. The latency of the orexin effect was 10–20 min. In two cats stimulation of the PPN with a maximum intensity of 50 μA did not abolish muscle tone when higher concentrations of orexin (200–500 μM) were injected into the PPN. *C*, orexin injections into the SNr also increased the threshold current required for PPN atonia. The effects were observed within 20 min. In *A–C*, the trials used the following concentrations of orexin: ○, 60 μM; □, 100 μM; grey squares, 200 μM; and ■, 500 μM. Higher concentrations of orexin produced stronger effects in each area. The effects continued for more than 100 min. *D*, the effects of injections of bicuculline into the PPN (▲ and △) and the SNr (■ and □) of orexins. Bicuculline (1 mM, 0.25 μl) was injected 20–30 min after the orexin injections; its effects were observed within 5 min, and lasted for more than 30 min. The filled and open symbols indicate orexin injections with concentrations of 1000 μM and 200 μM, respectively.

Fig. 8*B*). The stimuli which were applied to each site approximately 30–60 min after an orexin injection into the left PPN (Fig. 8*A*) resulted in an increased excitatory effect on the muscle tone from the CNF and the LC. This excitatory effect was accompanied by a prominent decrease in the inhibitory effects from the PRF and the dorsal and ventral PPN (Fig. 8*C*). Specifically, the duration and amplitude of the inhibitory effects were reduced, while those of the excitatory effects were increased. However, the effects of stimulating each site were not observed after 150–180 min (Fig. 8*D*). These findings suggest that the orexinergic projection to the PPN facilitates the activities of descending excitatory systems from the CNF and the LC, and suppresses the descending inhibitory system arising from the PPN.

Discussion

Canine narcolepsy is used as a model for understanding human narcolepsy (Nishino & Mignot, 1997). Orexin knockout mice have been also used to examine the control of behavioural states by orexin and pathological mechanisms of narcolepsy (Chemelli *et al.* 1999; Willie *et al.* 2003; Mochizuki *et al.* 2004). In the present study we used a decerebrated cat preparation in order to avoid

endogenous orexinergic activity. In addition, we combined a chemical stimulation technique with electrical stimulation so that we could examine the effects of orexin on the target areas controlling postural muscle tone and locomotion. We have now shown that orexinergic projections to the midbrain regulate the level of postural muscle tone and generation of locomotor behaviour. However, we need to clarify the limitations of the investigation and interpret the findings. For example, electrical stimulation may activate not only neuronal elements but also activate fibres. Chemical stimulation is suitable only for activation of neuronal elements and for supplementing any electrical stimulation. But we must consider that the effects of an injection of a drug depend on many factors including the receptor density of the cells at the injection site, the diffusion delay, and the time required for the recruitment of neurones (Takakusaki *et al.* 2003*a*, 2004*c*). Additionally, because the orexin system interferes with complex higher circuitry (Peyron *et al.* 1998) other than midbrain structures there is a need to integrate the present findings with previous results from studies of narcoleptic animals. In particular the present study could not examine emotional components unlike other experiments with narcoleptic animals.


Figure 8. Orexinergic modulation of descending pathways from the brainstem
A, an orexin injection site (an open arrow) and stimulus sites (O and ●) on a coronal section of the mesopontine tegmentum. *B*, from upper to lower: EMG activities induced by stimulating the MLR, locus coeruleus (LC), PRF, dorsal and ventral PPN. Stimulation of the MLR and the LC induced a mixture of excitatory and inhibitory effects. Stimulation of the PRF and the PPN suppressed EMG activities. *C* and *D*, the effects of an orexin injection into the PPN. EMG activities were recorded 30–60 min (*C*) and 150–180 min (*D*) after the injection of orexin. The EMG activity from the left soleus (Sol) muscles was rectified, integrated and averaged for 20 sweeps. Short train pulses of stimuli (3 trains, 5 ms intervals and 40 μA) were delivered to each site.

Disturbances of neurotransmitter systems in narcolepsy and their regulation by orexin

Disturbances of the noradrenergic system have been repeatedly reported in human narcolepsy patients with respect to the induction of cataplexy. The reports have indicated therefore, that an enhancement of the noradrenergic system powerfully reduces cataplexy (Aldrich *et al.* 1994; Schwartz, 2005). Studies which have used a canine narcolepsy model have also reported that various neurotransmitter systems are affected, including the noradrenergic (Fruhstorfer *et al.* 1989), adrenergic (Mignot *et al.* 1993), dopaminergic (Nishino *et al.* 1991; Reid *et al.* 1996; Kanbayashi *et al.* 2000), serotonergic (Nishino *et al.* 1993) and cholinergic systems (Nishino *et al.* 1988, 1995; Reid *et al.* 1994*a*,*b*). In particular, an increase in the activity of the noradrenergic system ameliorated cataplexy (Fruhstorfer *et al.* 1989). But an activation of the cholinergic system caused the symptoms to worsen (Nishino *et al.* 1988, 1995; Reid *et al.* 1994*a*,*b*). The deficiencies in these neurotransmitter systems were observed in both the brainstem (Reid *et al.* 1994*a*,*b*, 1996) and forebrain structures such as the amygdala (Guilleminault *et al.* 1998), the basal forebrain (Nishino *et al.* 1988, 1995) and the basal ganglia. In human narcolepsy patients, for example, an alteration of the dopaminergic system was observed in the basal ganglia (Eisensehr *et al.* 2003) and the amygdala (Aldrich *et al.* 1993).

Orexin neurones in the perifornical hypothalamus project to various regions in the nervous system (Peyron *et al.* 1998). Although most of the anatomical studies were performed in rats similar orexinergic projections have been reported in cats (Zhang *et al.* 2002, 2004). Monoaminergic neurones are major targets of the orexinergic system. In particular, a direct orexinergic projection to the LC may be in a position to enhance arousal and modulate plasticity in higher brain centres. These effects could occur through the developing noradrenergic neurones, which play an important role in modulating arousal, a vigilance state, selective attention, and memory (Horvath *et al.* 1999*b*; Soffin *et al.* 2002; van den Pol *et al.* 2002). The orexinergic system also excites dopaminergic (Korotkova *et al.* 2002), serotonergic (Liu *et al.* 2002; Soffin *et al.* 2004; Takahashi *et al.* 2005) and cholinergic neurones (Burlet *et al.* 2002; Takahashi *et al.* 2002; Wu *et al.* 2004; Fadel *et al.* 2005). Moreover the orexinergic system exerts excitatory actions on glutamatergic (Li *et al.* 2002), peptidergic (Horvath *et al.* 1999*a*) and GABAergic neurones (Korotkova *et al.* 2002; Wu *et al.* 2002) in various brain regions. Orexin neurones, in turn, receive either excitatory or inhibitory effects from these neurotransmitter systems (Fu *et al.* 2004; Li & van den Pol, 2005; Yamanaka *et al.* 2003). A loss of orexin may thus lead to a massive imbalance in these systems, resulting in the dysregulation of vigilance states.

It has been shown that canine narcolepsy is caused by exon skipping mutations of the Orexin-receptor-2 gene (Lin *et al.* 1999; Hungs *et al.* 2001; Willie *et al.* 2003). Orexin-2 receptor mRNA has been observed in the cerebral cortex, hippocampus, medial thalamic groups, hypothalamic nuclei, and brainstem regions including the raphe nuclei, the SNr and the PPN (Marcus *et al.* 2001). Orexin-2 receptors could therefore act to maintain a normal level of muscle tone. Because orexin A activates both orexin-1 and orexin-2 receptors (Willie *et al.* 2001), in the present study the effects of an injection of orexin A could be due to activation of orexin-2 receptors in the midbrain regions.

Orexinergic modulation of REM sleep and postural muscle tone

Orexin neurones project to the LDT and the PPN (Nambu *et al.* 1999; Peyron *et al.* 1998) where both cholinergic neurones (Armstrong *et al.* 1983; Rye *et al.* 1987; Span & Grofova, 1992; Takakusaki *et al.* 1996) and non-cholinergic neurones, including glutamatergic, GABAergic (Ottersen & Storm-Mathisen, 1984; Kosaka *et al.* 1988) and peptidergic neurones (Vincent *et al.* 1983) are located. In the present study orexin injections into the PPN or the SNr suppressed PPN-induced REM and atonia. The effects were eliminated, however, by subsequent injections of bicuculline into each area (Figs 4 and 5). One interpretation of the above findings is that the orexin effects are mediated by local GABAergic neurones in the PPN and GABAergic projection neurones arising from the SNr. This possibility is supported by the following evidence. First, orexin injections into the rat PPN increase the release of GABA in the PPN (Koyama *et al.* 2004). Second, GABAergic neurones in some brain areas are excited by orexin (Korotkova *et al.* 2002, 2003; Wu *et al.* 2002). Therefore the orexin effects can be mediated by the activation of GABAergic neurones, which in turn inhibit cholinergic PPN neurones (Torterolo *et al.* 2002; Pal & Mallick, 2004), resulting in the suppression of REM and atonia. Alternatively, orexin could stimulate presynaptic inhibitory inputs to the cholinergic neurones in the PPN, as has been shown in the LDT (Burlet *et al.* 2002). It was also demonstrated that orexins increase the frequency of GABAergic mIPSCs in the neurones of the hypothalamus (van den Pol *et al.* 1998) and hippocampus (Wu *et al.* 2002). Accordingly, orexin may act on presynaptic terminals of either local GABAergic interneurones in the PPN, or GABAergic neurones arising from the SNr, to facilitate the release of GABA. Immunohistochemical studies would be necessary to identify the orexinergic projections to the GABAergic neurones.

Several types of cholinergic neurones which are related to the sleep–awake cycle are located in the PPN/LDT. These neurones include those that are active during waking and REM sleep (W/REM-on neurones), and those that are specifically active during REM sleep (REM-on neurones). Desynchronization of the EEG and the regulation of wakefulness via ascending projections to the thalamus or cortex could be properties of W/REM-on neurones. A direct activation by orexin of W/REM-on neurones may therefore induce and maintain wakefulness. In contrast, REM-on neurones are thought to induce EEG desynchronization via ascending projections to forebrain structures, and muscular atonia during REM sleep via a descending projection to the PRF. We have demonstrated that non-cholinergic REM-on neurones in the PRF, which are excited by a cholinergic agonist, project to the medulla (Sakai & Koyama, 1996). An activation of cholinergic PPN neurones may thus excite the REM-on neurones in the PRF to suppress muscle tone via the pontomedullary reticulospinal tract (Takakusaki *et al.* 1994, 2001, 2003*b*). Because presumably the cholinergic REM-on neurones in the mesopontine tegmentum were excited by bicuculline, REM-on neurones in the PPN/LDT could be inhibited through GABA$_A$ receptors during waking (Sakai & Koyama, 1996). Ulloor *et al.* (2004) demonstrated that GABA$_B$ receptors on PPN cholinergic neurones were also involved in the regulation of REM sleep. It is therefore highly probable that, when orexin excites GABAergic neurones in the PPN/LDT, REM-on neurones are more selectively inhibited by GABA than W/REM-on neurones. This would result in suppression of REM sleep and muscular atonia. It has been reported by Xi *et al.* (2001) that an injection of orexin into the LDT facilitated wakefulness and suppressed REM sleep. The former effect may be attributed to a direct excitatory effect of orexin on the cholinergic neurones (Burlet *et al.* 2002; Takahashi *et al.* 2002), while the latter may be mediated through orexin-induced activity of GABAergic neurones.

Orexin injections into the PPN not only suppressed inhibitory effects from the PPN and the PRF but also enhanced excitatory effects from the MLR and the LC (Fig. 8). Descending monoaminergic systems, such as the coerulospinal and the raphespinal tracts, are muscle tone excitatory systems (Fung & Barnes, 1981; Sakai *et al.* 2000). There are also direct noradrenergic (Semba & Fibiger, 1992) and serotonergic projections (Honda & Semba, 1994) to the PPN/LDT and to the medial PRF (Semba, 1993). The noradrenergic projection inhibits the mesopontine cholinergic neurones (Koyama & Kayama, 1993; Leonald & Llinás, 1994). The serotonergic projection reduces the activity of the inhibitory system arising from the medial PRF (Takakusaki *et al.* 1993, 1994). Lai *et al.* (2001) have reported that there was a reduced release of noradrenaline and serotonin in the spinal cord during muscular atonia which was induced by electrical

or chemical stimulation applied to the medial PRF. They indicated that the activity of the coerulospinal and raphespinal tracts was inhibited by projections from the medial PRF to the LC and the raphe nuclei. Consequently, there are interconnections between the excitatory and inhibitory systems. The orexinergic projections to the midbrain therefore may control the level of muscle tone by counterbalancing these systems (see Takakusaki *et al.* 2004*b*).

Orexinergic control of locomotor behaviour

The MLR excites a spinal stepping generator to evoke locomotion via the medullary reticulospinal tract (Rossignol, 1996; Grillner, 2003). Signals from the MLR may also activate monoaminergic excitatory systems (see Mori, 1987). The lateral hypothalamus is known to be involved in the control of locomotion, especially of appetitive locomotion, while the medial hypothalamus probably controls defensive behaviour associated with darting locomotion (Sinnamon, 1993; Grillner *et al.* 1997). This emotional locomotor behaviour could be evoked through the projections from the hypothalamus to the midbrain, including the MLR and the medullary reticular formation (MRF) (Grillner *et al.* 1997). Torterolo *et al.* (2003) reported that orexinergic neurones expressed FOS only when somatomotor activity was present. The release of orexin in the lateral hypothalamus was higher during wakefulness than during non-REM sleep (Kiyashchenko *et al.* 2002). It was shown by Matsuzaki *et al.* (2002) that a central administration of orexins in rats significantly increased locomotor activity and induced changes in behaviour. Because an orexin injection into the MLR induced or facilitated locomotion (Fig. 3), an orexinergic projection to the MLR may be crucial for maintenance of the background excitability of the locomotor system. It follows that orexinergic projections to the midbrain cholinergic system, in addition to those to the dopaminergic and serotonergic systems, play a crucial role in the expression of emotional locomotor behaviour (Matsuzaki *et al.* 2002). It has been reported that during the initial 10–20 min in a novel environment orexin knockout mice displayed a smaller increase in locomotor activity than wild-type mice even though their wakefulness was normal (Mochizuki *et al.* 2004). The mesopontine tegmentum integrates the limbic and motor output systems, and concomitant sympathetic adjustments are likely to occur during complex behavioural changes (Smith & DeVito, 1984; Inglis & Winn, 1995; Winn *et al.* 1997). Krout *et al.* (2003) have shown that a considerable number of single orexinergic neurones in the lateral hypothalamus, and single cholinergic neurones in the PPN, directly or indirectly project to both the primary motor cortex and the stellate ganglion. This suggests that orexinergic and cholinergic neurones may integrate somatomotor

and autonomic functions, and affect different types of behaviour, such as arousal and sleep, and/or locomotion. All of these results suggest that an orexinergic system may separately control arousal systems and locomotor systems, and may link emotional stimuli to eliciting motivated locomotor behaviour.

Role of orexinergic projections to the midbrain in the pathogenesis of narcolepsy

Our interest was how the orexinergic projections to the midbrain contribute to the pathogenesis of narcolepsy. Muscular atonia has been induced by injections of orexins into the medial PRF (Kiyashchenko *et al.* 2001; Xi *et al.*


Figure 9. Role of orexinergic projections to the midbrain in the regulation of the locomotor system, REM and atonia systems, and possible mechanisms of induction of cataplexy in narcolepsy

A, a summary of the present results. Orexin excited the locomotor system and the SNr. The REM sleep generating (REM and atonia) system was inhibited by orexin through activation of GABAergic input, possibly from either local interneurones or SNr neurones. *B*, in a normal waking state orexin maintained an excitability of the locomotor system and suppressed the REM sleep generating system. Thus, emotional signals may elicit locomotor behaviour that is accompanied by muscle tone augmentation. *C*, in narcolepsy an orexin deficit may decrease the excitability of the locomotor system, whereas the excitability of the REM sleep generating system could be increased by a release from the inhibitory effects of orexin and nigral GABAergic input. Emotional signals may thus produce cataplexy. + and − signs indicate excitatory and inhibitory effects, respectively.

2002, 2003) and the MRF (Mileykovskiy *et al.* 2002). Under some circumstances orexinergic projections to the above regions may induce muscular atonia. In contrast, the present study revealed that orexinergic projections to the midbrain inhibited REM and atonia. The inhibition could be due to postsynaptic and/or presynaptic effects upon the soma and terminals of GABAergic neurones in the PPN and the SNr which facilitate the release of GABA, as discussed above. A sustained release of GABA cannot be maintained in the absence of orexin effects. These effects may increase the background excitability of systems generating REM and muscular atonia, and predispose affected individuals to attacks of cataplexy in narcolepsy. Therefore a higher sensitivity to orexin of the GABAergic neurones in the PPN and the SNr than of the REM sleep-related cholinergic neurones may underlie the pathogenesis of cataplexy. In this manner, cataplexy could occur by a disinhibition of the REM sleep generating system. In addition, the orexinergic projection may increase the level of muscle tone and facilitate locomotor behaviour (Fig. 9*A*).

Based on these considerations we have proposed a model for the orexinergic control of emotional motor behaviour and the disturbances that result in cataplexy in the narcoleptic state. In the normal waking state (Fig. 9*B*), the excitability of the locomotor system and the muscle tone excitatory system are maintained by tonic orexinergic input. The excitability of the REM sleep generating system could be suppressed by the GABAergic inhibition from the SNr or in the PPN. Emotional signals that reach the midbrain via the limbic and hypothalamic structures (Smith & Devito, 1984; Derryberry & Tucker, 1992) may increase muscle tone and/or induce emotional locomotor behaviour during wakefulness (Shaikh *et al.* 1984; Garcia-Rill *et al.* 2004; Skinner *et al.* 2004). However, in the narcoleptic state the excitability of both the locomotor system and the muscle tone excitatory system may be reduced because the orexinergic system is disturbed (Fig. 9*C*). But the orexin deficiency may result in an increase in background excitability of the REM sleep generating system via disinhibition from GABAergic inputs to PPN cholinergic neurones. Cataplexy in the narcoleptic state could be induced by a decrease in the activity of the descending excitatory systems (Siegel, 2004) as well as by an enhancement of the atonia-mediating system. Consequently, emotional signals could suddenly induce muscular atonia and this would result in cataplexy.

However, the above model may not be consistent with previous results. For example, according to this model, in which there is an absence of forebrain structures, a lack of orexin input may result in an increase in the background excitability of the REM sleep generating system. However, an increase in REM sleep has not been consistently observed in human narcolepsy (Aldrich, 1992), or in canine (Mitler & Dement, 1977) and mice (Mochizuki *et al.* 2004) narcoleptic models. Furthermore, a canine study has demonstrated that the cyclicity of the normal REM sleep interval is not disturbed in the affected animals (Nishino & Mignot, 1997). Such an inconsistency could be derived from the lack of a contribution by forebrain structures in this model, because orexins modulate various neurotransmitter systems in forebrain structures and the brainstem (Selbach *et al.* 2004). These neurotransmitter systems are altered during a narcoleptic state, as described above.

It is therefore critical to consider how forebrain structures contribute to the pathogenesis in narcolepsy. In fact, activity of cerebral cortex was altered in human narcolepsy patients (Oliviero *et al.* 2005). Mesopontine tegmentum receives volitional signals from the cerebral cortex and emotional signals from limbic structures such as the hippocampus and the amygdala (see Takakusaki *et al.* 2004*b*). Because the basal ganglia receive afferents from these two structures, the mesopontine tegmentum may play key roles in initiation, integration, selection, or switching of volitionally guided and emotionally triggered motor behaviour (Grillner *et al.* 1997; Jordan, 1998; Takakusaki *et al.* 2004*b*). We propose that descending and ascending systems from the brainstem may mediate changes of activity in the cerebral cortex, basal ganglia, limbic structures, and the brainstem, which would result in the generation of narcoleptic symptoms.

References

Alam MN, Gong H, Alam T, Jaganath R, McGinty D & Szymusiak R (2002). Sleep-waking discharge patterns of neurons recorded in the rat perifornical lateral hypothalamic area. *J Physiol* **538**, 619–631.

Aldrich MS (1992). Narcolepsy. *Neurol* **42**, 34–43.

Aldrich MS, Hollingsworth Z & Penney JB (1993). Autoradiographic studies of post-mortem human narcoleptic brain. *Neurophysiol Clin* **23**, 35–45.

Aldrich MS, Prokopowicz G, Ockert K, Hollingsworth Z, Penney JB & Albin RL (1994). Neurochemical studies of human narcolepsy: alpha-adrenergic receptor autoradiography of human narcoleptic brain and brainstem. *Sleep* **17**, 598–608.

Armstrong DA, Saper CB, Levey AI, Winer BH & Terry RD (1983). Distribution of cholinergic neurons in the rat brain demonstrated by the immunohistochemical localization of choline acethyltransferase. *J Comp Neurol* **216**, 53–68.

Berman A (1968). *The Brain Stem of the Cat: a Cytoarchitectonic Atlas with Stereotaxic Coordinates.* University of Wisconsin Press, Madison.

Burlet S, Tyler CJ & Leonard CS (2002). Direct and indirect excitation of laterodorsal tegmental neurons by hypocretin/orexin peptides: Implication for wakefulness and narcolepsy. *J Neurosci* **22**, 2862–2872.

Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C, Richardson JA, Williams SC, Xiong Y, Kisanuki Y, Fitch TE, Nakazato M, Hammer RE, Saper CB & Yanagisawa M (1999). Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. *Cell* **98**, 437–451.

Datta S & Hobson JA (1994). Neuronal activity in the caudolateral peribrachial pons: relationship to PGO waves and rapid eye movements. *J Neurophysiol* **71**, 95–109.

Datta S & Siwek DF (1997). Excitation of the brain stem pedunculopontine tegmentum cholinergic cells induces wakefulness and REM sleep. *J Neurophysiol* **77**, 2975–2988.

Derryberry D & Tucker DM (1992). Neural mechanisms of emotion. *J Consult Clin Psychol* **60**, 329–338.

Eisensehr I, Linke R, Tatsch K, von Lindeiner H, Kharraz B, Gildehaus FJ, Eberle R, Pollmacher T, Schuld A & Noachtar S (2003). Alteration of the striatal dopaminergic system in human narcolepsy. *Neurology* **60**, 1817–1819.

Estabrooke IV, McCarthy MT, Ko E, Chou TC, Chemelli RM, Yanagisawa M, Saper CB & Scammell TE (2001). Fos expression in orexin neurons varies with behavioral state. *J Neurosci* **21**, 1656–1662.

Fadel J, Pasumarthi R & Reznikov LR (2005). Stimulation of cortical acetylcholine release by orexin A. *Neuroscience* **130**, 541–547.

Ford B, Holmes CJ, Mainville L & Jones BE (1995). GABAergic neurons in the rat pontomesencephalic tegmentum: codistribution with cholinergic and other tegmental neurons projecting to the posterior lateral hypothalamus. *J Comp Neurol* **363**, 177–196.

Fruhstorfer B, Mignot E, Bowersox S, Nishino S, Dement WC & Guilleminault C (1989). Canine narcolepsy is associated with an elevated number of alpha 2-receptors in the locus coeruleus. *Brain Res* **500**, 209–214.

Fu LY, Acuna-Goycolea C & van den Pol AN (2004). Neuropeptide Y inhibits hypocretin/orexin neurons by multiple presynaptic and postsynaptic mechanisms: tonic depression of the hypothalamic arousal system. *J Neurosci* **24**, 8741–8751.

Fung SJ & Barnes CD (1981). Evidence of facilitatory coerulospinal action in lumbar motoneurons of cats. *Brain Res* **216**, 299–311.

Garcia-Rill E, Homma Y & Skinner RD (2004). Arousal mechanisms related to posture and locomotion: 1. Descending modulation. *Prog Brain Res* **143**, 283–290.

Grillner S (2003). The motor infrastructure: from ion channels to neuronal networks. *Nat Rev Neurosci* **4**, 573–586.

Grillner S, Georgopoulos AP & Jordan LM (1997). Selection and initiation of motor behavior. In *Neurons, Networks, and Motor Behavior*, ed. Stein PSG, Grillner S, Selverston AI & Stuart DG, pp. 3–19. MIT Press, Cambridge, MA, USA.

Grofova I & Zhou M (1998). Nigral innervation of cholinergic and glutamatergic cells in the rat mesopontine tegmentum. Light and electron microscopic anterograde tracing and immunohistochemical studies. *J Comp Neurol* **395**, 359–379.

Guilleminault C, Heinzer R, Mignot E & Black J (1998). Investigations into the neurologic basis of narcolepsy. *Neurology* **50**, S8–S15.

Habaguchi T, Takakusaki K, Saitoh K, Sugimoto J & Sakamoto T (2002). Medullary reticulospinal tract mediating the generalized motor inhibition in cats. II. Functional organization within the medullary reticular formation with respect to postsynaptic inhibition of forelimb and hindlimb motoneurons. *Neurosci* **113**, 65–77.

Honda T & Semba K (1994). Serotoergic synaptic input to cholinergic neurons in the rat mesopontine tegmentum. *Brain Res* **647**, 299–306.

Horvath TL, Diano S & van den Pol AN (1999*a*). Synaptic interaction between hypocretin (orexin) and neuropeptide Y cells in the rodent and primate hypothalamus: a novel circuit implicated in metabolic and endocrine regulations. *J Neurosci* **19**, 1072–1087.

Horvath TL, Peyron C, Diano S, Ivanov A, Aston-Jones G, Kilduff TS & van Den Pol AN (1999*b*). Hypocretin (orexin) activation and synaptic innervation of the locus coeruleus noradrenergic system. *J Comp Neurol* **415**, 145–159.

Hungs M, Fan J, Lin L, Lin X, Maki RA & Mignot E (2001). Identification and functional analysis of mutations in the hypocretin (orexin) genes of narcoleptic canines. *Genome Res* **11**, 531–539.

Inglis WL & Winn P (1995). The pedunculopontine tegmental nucleus: where the striatum meets the reticular formation. *Prog Neurobiol* **47**, 1–29.

Jordan LM (1998). Initiation of locomotion in mammals. *Ann N Y Acad Sci* **860**, 83–93.

Kanbayashi T, Honda K, Kodama T, Mignot E & Nishino S (2000). Implication of dopaminergic mechanisms in the wake-promoting effects of amphetamine: a study of D- and L-derivatives in canine narcolepsy. *Neuroscience* **99**, 651–659.

Kiyashchenko LI, Mileykovskiy BY, Lai YY & Siegel JM (2001). Increased and decreased muscle tone with orexin (hypocretin) microinjections in the locus coeruleus and pontine inhibitory area. *J Neurophysiol* **85**, 2008–2016.

Kiyashchenko LI, Mileykovskiy BY, Maidment N, Lam HA, Wu MF, John J, Peever J & Siegel JM (2002). Release of hypocretin (orexin) during waking and sleep states. *J Neurosci* **22**, 5282–5286.

Korotkova TM, Eriksson KS, Haas HL & Brown RE (2002). Selective excitation of GABAergic neurons in the substantia nigra of the rat by orexin/hypocretin in vitro. *Regul Pept* **104**, 83–89.

Korotkova TM, Sergeeva OA, Eriksson KS, Haas HL & Brown RE (2003). Excitation of ventral tegmental area dopaminergic and nondopaminergic neurons by orexins/hypocretins. *J Neurosci* **23**, 7–11.

Kosaka T, Tauchi M & Dahl J (1988). Cholinergic neurons containing GABA-like and/or glutamic acid decarboxylase-like immunoreactivities in various brain regions of the rat. *Expl Brain Res* **70**, 605–617.

Koyama Y & Kayama Y (1993). Mutual interactions among cholinergic, noradrenergic and serotonergic neurons studied by iontophoresis of these transmitters in rat brainstem nuclei. *Neurosci* **55**, 1117–1126.

Koyama Y & Sakai S (2000). Modulation of presumed cholinergic mesopontine tegmental neurons by acetylcholine and monoamines applied iontophoretically in unanesthetized cats. *Neurosci* **96**, 723–733.

Koyama Y, Takahashi K, Kodama T, Honda Y, Takakusaki K & Kayama Y (2004). Orexinergic inhibition on the mesopontine cholinergic neurons mediated through GABAergic neurons. *Soc Neurosci Abs* 318.3.

Koyama Y, Takahashi K, Kodama T & Kayama Y (2003). State-dependent activity of neurons in the perifornical hypothalamic area during sleep and waking. *Neurosci* **119**, 1209–1219.

Krout KE, Mettenleiter TC & Loewy AD (2003). Single CNS neurons link both central motor and cardiosympathetic systems: a double-virus tracing study. *Neurosci* **118**, 853–866.

Lai YY, Clements JR & Siegel JM (1993). Glutamatergic and cholinergic projections to the pontine inhibitory area identified with horseradish peroxidase retrograde transport and immunohistochemistry. *J Comp Neurol* **336**, 321–330.

Lai YY, Kodama T & Siegel JM (2001). Changes in monoamine release in the ventral horn and hypoglossal nucleus linked to pontine inhibition of muscle tone: an in vivo microdialysis study. *J Neurosci* **21**, 7384–7391.

Lee MG, Hassani OK & Jones BE (2005). Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle. *J Neurosci* **25**, 6716–6720.

Leonald CS & Llinás R (1994). Serotonergic and cholinergic inhibition of mesopontine cholinergic neurons controlling REM sleep; an in vitro electrophysiological study. *Neurosci* **59**, 309–330.

Li Y, Gao XB, Sakurai T & van den Pol AN (2002). Hypocretin/Orexin excites hypocretin neurons via a local glutamate neuron – A potential mechanism for orchestrating the hypothalamic arousal system. *Neuron* **36**, 1169–1181.

Li Y & van den Pol AN (2005). Direct and indirect inhibition by catecholamines of hypocretin/orexin neurons. *J Neurosci* **25**, 173–183.

Lin L, Faraco J, Li R, Kadotani H, Rogers W, Lin X, Qiu X, de Jong PJ, Nishino S & Mignot E (1999). The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. *Cell* **98**, 365–376.

Liu RJ, van den Pol AN & Aghajanian GK (2002). Hypocretins (orexins) regulate serotonin neurons in the dorsal raphe nucleus by excitatory direct and inhibitory indirect actions. *J Neurosci* **22**, 9453–9464.

Marcus JN, Aschkenasi CJ, Lee CE, Chemelli RM, Saper CB, Yanagisawa M & Elmquist JK (2001). Differential expression of orexin receptors 1 and 2 in the rat brain. *J Comp Neurol* **435**, 6–25.

Matsuzaki I, Sakurai T, Kunii K, Nakamura T, Yanagisawa M & Goto K (2002). Involvement of the serotonergic system in orexin-induced behavioral alterations in rats. *Regul Pept* **104**, 119–123.

McCarley RW, Greene RW, Rainnie D & Portas CM (1995). Brainstem neuromodulation and REM sleep. *Seminars Neurosci* **7**, 341–354.

Mignot E, Renaud A, Nishino S, Arrigoni J, Guilleminault C & Dement WC (1993). Canine cataplexy is preferentially controlled by adrenergic mechanisms: evidence using monoamine selective uptake inhibitors and release enhancers. *Psychopharmacology (Berl)* **113**, 76–82.

Mileykovskiy BY, Kiyashchenko LI & Siegel JM (2002). Muscle tone facilitation and inhibition after orexin-a (hypocretin-1) microinjections into the medial medulla. *J Neurophysiol* **87**, 2480–2489.

Mileykovskiy BY, Kiyashchenko LI & Siegel JM (2005). Behavioral correlates of activity in identified hypocretin/orexin neurons. *Neuron* **46**, 787–798.

Mitani A, Ito K, Hallanger AE, Wainer BH, Kataoka K & McCarley RW (1988). Cholinergic projections from the laterodorsal and pedunculopontine tegmental nuclei to the pontine giganotocellular tegmental field in the cat. *Brain Res* **451**, 397–402.

Mitler MM & Dement WC (1977). Sleep studies on canine narcolepsy. pattern and cycle comparisons between affected and normal dogs. *Electroencephalogr Clin Neurophysiol* **43**, 691–699.

Mochizuki T, Crocker A, McCormack S, Yanagisawa M, Sakurai T & Scammell TE (2004). Behavioral state instability in orexin knock-out mice. *J Neurosci* **24**, 6291–6300.

Mori S (1987). Integration of posture and locomotion in acute decerebrate cats and in awake, free moving cats. *Prog Neurobiol* **28**, 161–196.

Nambu T, Sakurai T, Mizukami K, Hosoya Y, Yanagisawa M & Goto K (1999). Distribution of orexin neurons in the adult rat brain. *Brain Res* **827**, 243–260.

Nishino S (2003). The hypocretin/orexin system in health and disease. *Biol Psychiatry* **54**, 87–95.

Nishino S, Arrigoni J, Shelton J, Dement WC & Mignot E (1993). Desmethyl metabolites of serotonergic uptake inhibitors are more potent for suppressing canine cataplexy than their parent compounds. *Sleep* **16**, 706–712.

Nishino S, Arrigoni J, Valtier D, Miller JD, Guilleminault C, Dement WC & Mignot E (1991). Dopamine D2 mechanisms in canine narcolepsy. *J Neurosci* **11**, 2666–2671.

Nishino S, Honda K, Riehl J, Okura M & Mignot E (1988). Neuronal activity in the cholinoceptive basal forebrain of freely moving narcoleptic dobermans. *Neuroreport* **9**, 3653–3661.

Nishino S & Mignot E (1997). Pharmacological aspects of human and canine narcolepsy. *Prog Neurobiol* **52**, 27–78.

Nishino S, Tafti M, Reid MS, Shelton J, Siegel JM, Dement WC & Mignot E (1995). Muscle atonia is triggered by cholinergic stimulation of the basal forebrain. Implication for the pathophysiology of canine narcolepsy. *J Neurosci* **15**, 4806–4814.

Oliviero A, Della Marca G, Tonali PA, Pilato F, Saturno E, Dileone M, Versace V, Mennuni G & Di Lazzaro V (2005). Functional involvement of cerebral cortex in human narcolepsy. *J Neurol* **252**, 56–61.

Ottersen O & Storm-Mathisen J (1984). Glutamate- and GABA-containing neurons in the mouse and rat brain, as demonstrated with a new immunohistochemical technique. *J Comp Neurol* **229**, 374–392.

Pal D & Mallick BN (2004). GABA in pedunculopontine tegmentum regulates spontaneous rapid eye movement sleep by acting on GABA$_A$ receptors in freely moving rats. *Neurosci Lett* **365**, 200–204.

Peyron C, Tighe DK, van den Pol AN, de Lecea L, Heller HC, Sutcliffe JG & Kilduff TS (1998). Neurons containing hypocretin (orexin) project to multiple neuronal systems. *J Neurosci* **18**, 9996–10015.

Reid MS, Siegel JM, Dement WC & Mignot E (1994*a*). Cholinergic mechanisms in canine narcolepsy – II. Acetylcholine release in the pontine reticular formation is enhanced during cataplexy. *Neuroscience* **59**, 523–530.

Reid MS, Tafti M, Geary JN, Nishino S, Siegel JM, Dement WC & Mignot E (1994*b*). Cholinergic mechanisms in canine narcolepsy – I. Modulation of cataplexy via local drug administration into the pontine reticular formation. *Neuroscience* **59**, 511–522.

Reid MS, Tafti M, Nishino S, Sampathkumaran R, Siegel JM & Mignot E (1996). Local administration of dopaminergic drugs into the ventral tegmental area modulates cataplexy in the narcoleptic canine. *Brain Res* **733**, 83–100.

Rossignol S (1996). Neural control of stereotypic limb movements. In *Handbook of Physiology*, section 12, *Exercise: Regulation and Integration of Multiple Systems*, ed. Rowell LB & Shepherd JT, pp. 173–216. Oxford University Press, New York.

Rye BD, Saper CB, Lee HJ & Wainer BH (1987). Pedunculopontine tegmental nucleus of the rat: cytoarchitecture, cytochemistry, and some extrapyramidal connections of the mesopontine tegmentum. *J Comp Neurol* **259**, 483–528.

Saitoh K, Hattori S, Song WJ, Isa T & Takakusaki K (2003). Nigral GABAergic inhibition upon cholinergic neurons in the rat pedunculopontine tegmental nucleus. *Eur J Neurosci* **18**, 879–886.

Sakai K & Jouvet M (1980). Brain stem PGO-on cells projecting directly to the cat dorsal lateral geniculate nucleus. *Brain Res* **194**, 500–505.

Sakai K & Koyama Y (1996). Are there cholinergic and non-cholinergic paradoxical sleep-on neurones in the pons? *Neuroreport* **7**, 2449–2453.

Sakai M, Matsunaga M, Kubota A, Yamanishi Y & Nishizawa Y (2000). Reduction in excessive muscle tone by selective depletion of serotonin in intercollicularly decerebrated rats. *Brain Res* **860**, 104–111.

Sakurai T (2002). Roles of orexins in regulation of feeding and wakefulness. *Neuroreport* **13**, 987–995.

Saper CB, Chou TC & Scammell TE (2001). The sleep switch: hypothalamic control of sleep and wakefulness. *Trends Neurosci* **24**, 726–731.

Schwartz JR (2005). Modafinil: new indications for wake promotion. *Expert Opin Pharmacother* **6**, 115–129.

Selbach O, Doreulee N, Bohla C, Eriksson KS, Sergeeva OA, Poelchen W, Brown RE & Haas HL (2004). Orexins/hypocretins cause sharp wave- and theta-related synaptic plasticity in the hippocampus via glutamatergic, gabaergic, noradrenergic, and cholinergic signaling. *Neuroscience* **127**, 519–528.

Semba K (1993). Aminergic and cholinergic afferents to REM sleep induction regions of the pontine reticular formation in the rat. *J Comp Neurol* **330**, 543–556.

Semba K & Fibiger HC (1992). Afferent connections of the laterodorsal and the pedunculopontine tegmental nuclei in the rat. a retro- and anterograde transport and immunohistochemical study. *J Comp Neurol* **323**, 387–410.

Shaikh MB, Brutus M, Siegel BH & Siegel A (1984). Differential control of aggression by the midbrain. *Expl Neurol* **83**, 436–442.

Siegel JM (2004). Hypocretin (orexn): Role in normal behavior and neuropathology. *Ann Rev Psychol* **55**, 125–148.

Sinnamon HM (1993). Preoptic and hypothalamic neurons and the initiation of locomotion in the anesthetized rat. *Prog Neurobiol* **41**, 323–344.

Skinner RD, Homma Y & Garcia-Rill E (2004). Arousal mechanisms related to posture and locomotion: 2. Ascending modulation. *Prog Brain Res* **143**, 291–298.

Smith OA & DeVito JL (1984). Central neural integration for the control of autonomic responses associated with emotion. *Ann Rev Neurosci* **7**, 43–65.

Snider RS & Niemer WT (1961). *A Stereotaxic Atlas of the Cat Brain.* University of Chicago Press, Chicago.

Soffin EM, Evans ML, Gill CH, Harries MH, Benham CD & Davies CH (2002). SB-334867-A antagonises orexin mediated excitation in the locus coeruleus. *Neuropharmacology* **42**, 127–133.

Soffin EM, Gill CH, Brough SJ, Jerman JC & Davies CH (2004). Pharmacological characterisation of the orexin receptor subtype mediating postsynaptic excitation in the rat dorsal raphe nucleus. *Neuropharmacology* **46**, 1168–1176.

Spann BM & Grofova I (1992). Cholinergic and non-cholinergic neurons in the rat pedunculopontine tegmental nucleus. *Anat Embryol* **186**, 215–227.

Taheri S, Zeitzer JM & Mignot E (2002). The role of hypocretins (orexins) in sleep regulation and narcolepsy. *Ann Rev Neurosci* **25**, 283–313.

Takahashi K, Koyama Y, Kayama Y & Yamamoto M (2002). Effects of orexin on the laterodorsal tegmental neurons. *Psychiatry Clin Neurosci* **56**, 335–336.

Takahashi K, Wang Q-P, Guan J-L, Kayama Y, Shioda S & Koyama Y (2005). State-dependent effects of orexin on the serotonergic dorsal raphe neuronsin the rat. *Reg Peptide* **126**, 43–47.

Takakusaki K, Habaguchi T, Ohinata-Sugimoto J, Saitoh K & Sakamoto T (2003*a*). Basal ganglia efferents to the brainstem centers controlling postural muscle tone and locomotion: a new concept for understanding motor disorders in basal ganglia dysfunction. *Neurosci* **119**, 293–308.

Takakusaki K, Habaguchi T, Saitoh K & Kohyama J (2004*a*). Changes in the excitability of hindlimb motoneurons during muscular atonia induced by stimulating the pedunculopontine tegmental nucleus in cats. *Neurosci* **124**, 467–480.

Takakusaki K, Kohyama J & Matsuyama K (2003*b*). Medullary reticulospinal tract mediating a generalized motor inhibition in cats. III. Functional organization of spinal interneurons in the lower lumbar segments. *Neurosci* **121**, 731–746.

Takakusaki K, Kohyama J, Matsuyama K & Mori S (1993). Synaptic mechanisms acting on lumbar motoneurons during postural augmentation induced by serotonin injection into the rostral pontine reticular formation in decerebrate cats. *Expl Brain Res* **93**, 471–482.

Takakusaki K, Kohyama J, Matsuyama K & Mori S (2001). Medullary reticulospinal tract mediating the generalized motor inhibition in cats: parallel inhibitory mechanisms acting on motoneurons and on interneuronal transmission in reflex pathways. *Neurosci* **103**, 511–527.

Takakusaki K, Saitoh K, Harada H & Kashiwayanagi M (2004*b*). Role of basal ganglia–brainstem pathways in the control of motor behaviors. *Neuroscience Res* **50**, 137–151.

Takakusaki K, Saitoh K, Harada H, Okumura T & Sakamoto T (2004*c*). Evidence for a role of basal ganglia in the regulation of rapid eye movement sleep by electrical and chemical stimulation for the pedunculopontine tegmental nucleus and the substantia nigra pars reticulata in decerebrate cats. *Neurosci* **124**, 207–220.

Takakusaki K, Shimoda N, Matsuyama K & Mori S (1994). Discharge properties of medullary reticulospinal neurons during postural changes induced by intrapontine injections of carbachol, atropine and serotonin, and their functional linkages to hindlimb motoneurons in cats. *Expl Brain Res* **99**, 361–374.

Takakusaki K, Shiroyama T, Yamamoto T & Kitai ST (1996). Cholinergic and non- cholinergic tegmental pedunculopontine projection neurons in rats revealed by intracellular labeling. *J Comp Neurol* **371**, 345–361.

Takakusaki K, Takahashi K, Saitoh K, Harada H, Okumura T & Koyama Y (2004*d*). Orexinergic projections to the midbrain mediate alternation of emotional behavioral states from locomotion to cataplexy. *Soc Neurosci Abs* 534.4.

Torterolo P, Morales FR & Chase MH (2002). GABAergic mechanisms in the pedunculo-pontine tegmental nucleus of the cat promote active (REM) sleep. *Brain Res* **944**, 1–9.

Torterolo P, Yamuy J, Sampogna S, Morales FR & Chase MH (2003). Hypocretinergic neurons are primarily involved in activation of the somatomotor system. *Sleep* **26**, 25–28.

Ulloor J, Mavanji V, Saha S, Siwek DF & Datta S (2004). Spontaneous REM sleep is modulated by the activation of the pedunculopontine tegmental GABA$_B$ receptors in the freely moving rat. *J Neurophysiol* **91**, 1822–1831.

van den Pol AN, Gao XB, Obrietan K, Kilduff TS & Belousov AB (1998). Presynaptic and postsynaptic actions and modulation of neuroendocrine neurons by a new hypothalamic peptide, hypocretin/orexin. *J Neurosci* **18**, 7962–7971.

van den Pol AN, Ghosh PK, Liu RJ, Li Y, Aghajanian GK & Gao XB (2002). Hypocretin (orexin) enhances neuron activity and cell synchrony in developing mouse GFP-expressing locus coeruleus. *J Physiol* **541**, 169–185.

Vanni-Mercier G & Debilly G (1998). A key role for the caudoventral pontine tegmentum in the simultaneous generation of eye saccades in bursts and associated ponto-geniculo-occipital waves during paradoxical sleep in the cat. *Neurosci* **86**, 571–585.

Vincent SR, Satoh K, Armstrong DM & Fibiger HC (1983). Substance P in the ascending cholinergic reticular system. *Nature* **306**, 688–691.

White SR & Fung SJ (1989). Serotonin depolarizes cat spinal motoneurons in situ and decreases motoneuron afterhyperpolarizing potentials. *Brain Res* **502**, 205–213.

Willie JT, Chemelli RM, Sinton CM, Tokita S, Williams SC, Kisanuki YY, Marcus JN, Lee C, Elmquist JK, Kohlmeier KA, Leonard CS, Richardson JA, Hammer RE & Yanagisawa M (2003). Distinct narcolepsy syndromes in orexin receptor-2 and orexin null mice. Molecular genetic dissection of non-REM and REM sleep regulatory processes. *Neuron* **38**, 715–730.

Willie JT, Chemelli RM, Sinton CM & Yanagisawa M (2001). To eat or to sleep? Orexin in the regulation of feeding and wakefulness. *Annu Rev Neurosci* **24**, 429–458.

Winn P, Brown VJ & Inglis WL (1997). On the relationships between the striatum and the pedunculopontine tegmental nucleus. *Crit Rev Neurobiol* **11**, 241–261.

Wu M, Zaborszky L, Hajszan T, van den Pol AN & Alreja M (2004). Hypocretin/orexin innervation and excitation of identified septohippocampal cholinergic neurons. *J Neurosci* **24**, 3527–3536.

Wu M, Zhang Z, Leranth C, Xu C, van den Pol AN & Alreja M (2002). Hypocretin increases impulse flow in the septohippocampal GABAergic pathway: implications for arousal via a mechanism of hippocampal disinhibition. *J Neurosci* **22**, 7754–7765.

Xi MC, Fung SJ, Yamuy J, Morales FR & Chase MH (2002). Induction of active (REM) sleep and motor inhibition by hypocretin in the nucleus pontis oralis of the cat. *J Neurophysiol* **87**, 2880–2888.

Xi MC, Fung SJ, Yamuy J, Morales FR & Chase MH (2003). Hypocretinergic facilitation of synaptic activity of neurons in the nucleus pontis oralis of the cat. *Brain Res* **976**, 253–258.

Xi MC, Morales FR & Chase MH (2001). Effects on sleep and wakefulness of the injection of hypocretin-1 (orexin-A) into the laterodorsal tegmental nucleus of the cat. *Brain Res* **901**, 259–264.

Yamanaka A, Muraki Y, Tsujino N, Goto K & Sakurai T (2003). Regulation of orexin neurons by the monoaminergic and cholinergic systems. *Biochem Biophys Res Commun* **303**, 120–129.

Zhang J-H, Sampogna S, Morales FR & Chase MH (2002). Co-localization of hypocretin-1 and hypocretin-2 in the cat hypothalamus and brainstem. *Peptides* **23**, 1479–1483.

Zhang J-H, Sampogna S, Morales FR & Chase MH (2004). Distribution of hypocretin (orexin) immunoreactivity in the feline pons and medulla. *Brain Res* **995**, 205–217.

Acknowledgements